Abstract
In recent years, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been shown to play important roles in tumor biological function. The aim of this study was to investigate the diagnostic and prognostic value of lncRNA H19 and miR-21 expression in non-small-cell lung cancer (NSCLC). H19 and miR-21 expression was measured in tumor tissues and corresponding non-tumor lung tissues from 200 patients by quantitative reverse transcription polymerase chain reaction. Moreover, the in vitro and in vivo effects of H19 knock out in A549 cells were investigated. Expression of both H19 and miR-21 was significantly higher in lung tissues from patients with NSCLC than in normal lung tissues. Increased expression of H19 and miR-21 was positively correlated with advanced tumor-node-metastasis stage and tumor size. miR-21 expression was highest in stage I and II NSCLC, whereas H19 expression was highest in stage III and IV NSCLC. Knockout of H19 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. The results show that H19 may mainly contributes to the progression of NSCLC, and its expression levels can reflect the invasive and metastatic status to some extent. miR-21 expression more likely plays an important role in early stage NSCLC. Moreover, H19 and miR-21 interact in the regulation of NSCLC, and with greater expression of both H19 and miR-21, overall survival decreased. The combination of H19 and miR-21 may have diagnostic value in NSCLC and represent a target for new NSCLC treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. Cancer J Clin 2014; 64: 9–29.
Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo Ml . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359–386.
Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O’Brien ME . Treatment options for small cell lung cancer—do we have more choice? Br J Cancer 2010; 102: 629–638.
Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB . Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008; 18: 1433–1445.
Ginger MR, Shore AN, Contreras A, Rijnkels M, Miller J, Gonzalez-Rimbau MF . Anoncoding RNAis a potential marker of cell fate during mammary gland development. Proc Natl Acad Sci USA 2006; 103: 5781–5786.
Gao L, Mai A, Li X, Lai Y, Zheng J, Yang Q . LncRNADQ786227- mediated cell malignant transformation induced by benzo(a)pyrene. Toxicol Lett 2013; 223: 205–210.
Batista PJ, Chang HY . Long noncoding RNAs: cellular address codes in development and disease. Cell 2013; 152: 1298–1307.
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A et al. Landscape of transcription in human cells. Nature 2012; 489: 101–108.
Enfield KS, Pikor LA, Martinez VD, Lam WL . Mechanistic roles of noncoding RNAs in lung cancer biology and their clinical implications. Genet Res Int 2012; 2012: 737416.
Yang Q, Zhang S, Liu H, Wu Jl . Oncogenic role of long noncodingRNA AF118081 inanti-benzoapyrene-trans-7,8-dihydrodiol-9,10-epoxide-transformed 16HBE cells. Toxicol Lett 2014; 229: 430–439.
Mercer TR, Dinger ME, Mattick JS . Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155–159.
Ng SY, Lin L, Soh BS, Stanton LW . Long noncoding RNAs in development and disease of the central nervous system. Trends Genet 2013; 29: 461–468.
Zhang J, Zhang P, Wang L, Piao HL, Ma L . Long non-coding RNA HOTAIR in carcinogenesis and metastasis. Acta Biochim Biophys Sin 2014; 46: 1–5.
Qiu MT, Hu JW, Yin R, Xu L . Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol: J Int Soc Oncodev Biol Med 2013; 34: 613–620.
Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, Kondo S . Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002; 420: 563–573.
Ji P, Diederichs S, WangW, Boing S, Metzger R, Schneider PM . MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031–8041.
Shi X, Sun M, Liu H, Yao Y, Song Y . Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett 2013; 339: 159–166.
Chan JA, Krichevsky AM, Kosik KS . MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029–6033.
Yaodong Z, Bo S . The significance and correlation of microRNA-21 expression with biological features and prognosis of neuroblastoma (NB). Cancer Control 2016; 23: 78–84.
Si ML, Zhu S, Wu H, LU Z, Wu F, Mo YY et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799–2803.
Nagano T, Fraser P . No-nonsense functions for long noncoding RNAs. Cell 2011; 145: 178–181.
Park JY, Lee JE, Park JB, Yoo H, Lee SH, Kim JH . Roles of long noncoding RNAs on tumorigenesis and glioma development. Brain Tumor Res Treatment 2014; 2: 1–6.
Ponjavic J, Ponting CP, Lunter G . Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs. Genome Res 2007; 17: 556–565.
Zhou Y, Sheng B . Association of microRNA 21 With Biological Features and Prognosis of Neuroblastoma. Cancer Control 2016; 23: 78–84.
Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X . Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res 2013; 354: 891–896.
Mourtada-Maarabouni M, Williams GT . Growth arrest on inhibition of nonsense-mediated decay is mediated by noncoding RNA GAS5. BioMed Res Int 2013; 13: 358D15.
Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jockel KH . Evaluation of long noncoding RNA MALAT1 as a candidate bloodbased biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes 2013; 6: 518.
Tay Y, Rinn J, Pandolfi PP . The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344–352.
Anko ML, Muller-McNicoll M, Brandl H . The RNA binding landscapes of two SR proteins reveal unique functions and binding to diverse RNA classes. Genome Biol 2012; 13: R17–R32.
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W . The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21(WAF1/CIP1) expression. PLoS ONE 2013; 8: e77293.
Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133–144.
Ling H, Fabbri M, Calin GA . MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847–865.
Acknowledgements
We thank Reginald C. Tsang, MD and Hao WU, MD, for help in editing this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zhou, Y., Sheng, B., Xia, Q. et al. Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer. Cancer Gene Ther 24, 317–324 (2017). https://doi.org/10.1038/cgt.2017.20
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2017.20
This article is cited by
-
LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside
Cell Death Discovery (2022)
-
Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors
Clinical and Experimental Medicine (2022)
-
Noncoding RNAs in tumor metastasis: molecular and clinical perspectives
Cellular and Molecular Life Sciences (2021)
-
Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma
Cell Death & Disease (2020)
-
Clinical utility of circulating non-coding RNAs — an update
Nature Reviews Clinical Oncology (2018)